Subscribe
Be the first with the news that moves the market- Mednow (MNOW) reported Q1/23 revenue increased approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year
- Mednow patient count by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22
- Reduced costs by 30 per cent, achieved additional cost savings post-Q1’23 to further reduce cash burn
- Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results
- Mednow is a healthcare technology company
- Mednow Inc. (MNOW) opened trading at $0.29 per share
Mednow (MNOW) has released its financial results for the period ending October 31, 2022 (Q1 2023).
In fiscal Q1, revenue increased by approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year
Mednow’s patient count increased by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22.
Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results.
Mednow is a Canadian-based healthcare technology company. Mednow.ca provides virtual pharmacy and telemedicine services, as well as doctor home visits.
Mednow Inc. (MNOW) opened trading at $0.29 per share.
